SSY Group's indocyanine green drug approved in China

SSY Group Limited announced its indocyanine green product has secured registration approval from China's National Medical Products Administration. This approval allows the substance to be used as a bulk drug for preparations on the market, marking a significant step in the group's product development efforts.

Indocyanine green is a diagnostic agent with multiple applications, including the detection of various liver conditions such as cirrhosis, liver fibrosis, chronic hepatitis, and drug-induced liver diseases. It helps assess the extent of liver damage and its reserve function. Additionally, the drug is valuable in choroidal angiography for pinpointing the location of choroidal diseases.

The company issued this announcement voluntarily to keep shareholders and potential investors updated on the latest business developments. As of September 9, 2025, the board of directors includes Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung, and Ms. Qu Wanrong as executive directors, with Mr. Liu Wenjun as a non-executive director, and Mr. Wang Yibing, Mr. Chow Kwok Wai, and Mr. Jiang Guangce serving as independent non-executive directors. Mr. Chow Hing Yeung also holds the position of executive director and company secretary.